The role of complement in biomaterial-induced inflammation

被引:302
作者
Nilsson, Bo
Ekdahl, Kristina Nilsson [1 ]
Mollnes, Tom Eirik
Lambris, John D.
机构
[1] Univ Uppsala Hosp, Dept Radiol Oncol & Clin Immunol, Div Clin Immunol, Rudbeck Lab, Uppsala, Sweden
[2] Univ Kalmar, Dept Chem & Biomed Sci, Kalmar, Sweden
[3] Rikshosp Univ Hosp, Inst Immunol, Oslo, Norway
[4] Univ Oslo, N-0316 Oslo, Norway
[5] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
complement; biomaterial; coagulation; inflammation; cross-talk;
D O I
10.1016/j.molimm.2006.06.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Biomaterials are regularly used in various types of artificial tissues and organs, such as oxygenators, plasmapheresis equipment, hemodialysers, catheters, prostheses, stents, vascular grafts, miniature pumps, sensors and heart aids. Although progress has been made regarding bioincompatibility, many materials and procedures are associated with side effects, in particular bioincompatibility-induced inflammation, infections and subsequent loss of function. After cardiopulmonary bypass, coagulopathies can occur and lead to cognitive disturbances, stroke and extended hospitalization. Hemodialysis is associated with anaphylatoid reactions that cause whole-body inflammation and may contribute to accelerated arteriosclerosis. Stents cause restenosis and, in severe cases, thrombotic reactions. This situation indicates that there is still a need to try to understand the mechanisms involved in these incompatibility reactions in order to be able to improve the biomaterials and to develop treatments that attenuate the reactions and thereby reduce patients' discomfort, treatment time and cost. This overview deals with the role of complement in the incompatibility reactions that occur when biomaterials come in contact with blood and other body fluids. (C) 2006 Published by Elsevier Ltd.
引用
收藏
页码:82 / 94
页数:13
相关论文
共 109 条
[41]   Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1 [J].
Hourcade, D ;
Liszewski, MK ;
Krych-Goldberg, M ;
Atkinson, JP .
IMMUNOPHARMACOLOGY, 2000, 49 (1-2) :103-116
[42]   Heparin-coated cardiopulmonary bypass circuits: current status [J].
Hsu, LC .
PERFUSION-UK, 2001, 16 (05) :417-428
[43]   Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein [J].
Huang, J ;
Kim, LJ ;
Mealey, R ;
Marsh, HC ;
Zhang, Y ;
Tenner, AJ ;
Connolly, ES ;
Pinsky, DJ .
SCIENCE, 1999, 285 (5427) :595-599
[44]   Generation of C5a in the absence of C3: a new complement activation pathway [J].
Huber-Lang, Markus ;
Sarma, J. Vidya ;
Zetoune, Firas S. ;
Rittirsch, Daniel ;
Neff, Thomas A. ;
McGuire, Stephanie R. ;
Lambris, John D. ;
Warner, Roscoe L. ;
Flierl, Michael A. ;
Hoesel, Laszlo M. ;
Gebhard, Florian ;
Younger, John G. ;
Drouin, Scott M. ;
Wetsel, Rick A. ;
Ward, Peter A. .
NATURE MEDICINE, 2006, 12 (06) :682-687
[45]   Protection of innate immunity by C5aR antagonist in septic mice [J].
Huber-Lang, MS ;
Riedeman, NC ;
Sarma, JV ;
Younkin, EM ;
McGuire, SR ;
Laudes, IJ ;
Lu, KT ;
Guo, RF ;
Neff, TA ;
Padgaonkar, VA ;
Lambris, JD ;
Spruce, L ;
Mastellos, D ;
Zetoune, FS ;
Ward, PA .
FASEB JOURNAL, 2002, 16 (12) :1567-1574
[46]  
Ikeda K, 1997, THROMB HAEMOSTASIS, V77, P394
[47]  
Kaplan Mariana, 2002, Curr Opin Investig Drugs, V3, P1017
[48]   Platelet activation in hemolytic uremic syndrome [J].
Karpman, D ;
Manea, M ;
Vaziri-Sani, F ;
Ståhl, AL ;
Kristoffersson, AC .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (02) :128-145
[49]   Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin [J].
Katragadda, Madan ;
Magotti, Paola ;
Sfyroera, Georgia ;
Lambris, John D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (15) :4616-4622
[50]   IDENTIFICATION AND SYNTHESIS OF A RECEPTOR-BINDING SITE OF HUMAN ANAPHYLATOXIN C5A [J].
KAWAI, M ;
QUINCY, DA ;
LANE, B ;
MOLLISON, KW ;
LULY, JR ;
CARTER, GW .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (07) :2068-2071